Compare SF & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SF | PODD |
|---|---|---|
| Founded | 1890 | 2000 |
| Country | United States | United States |
| Employees | 9000 | N/A |
| Industry | Investment Bankers/Brokers/Service | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6B | 10.3B |
| IPO Year | N/A | 2007 |
| Metric | SF | PODD |
|---|---|---|
| Price | $83.34 | $142.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 21 |
| Target Price | $90.33 | ★ $341.48 |
| AVG Volume (30 Days) | 1.2M | ★ 1.7M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.67 |
| Revenue | N/A | ★ $2,708,100,000.00 |
| Revenue This Year | $14.58 | $24.55 |
| Revenue Next Year | $8.03 | $19.18 |
| P/E Ratio | ★ $20.53 | $52.17 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $67.81 | $126.40 |
| 52 Week High | $134.74 | $354.88 |
| Indicator | SF | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 65.03 | 34.93 |
| Support Level | $68.36 | N/A |
| Resistance Level | $84.33 | $167.98 |
| Average True Range (ATR) | 1.96 | 6.45 |
| MACD | 0.18 | -2.89 |
| Stochastic Oscillator | 75.68 | 27.73 |
Stifel Financial is a diversified financial-services provider that generates revenue from wealth management, investment banking, and lending. The firm was founded in 1890 as a St. Louis-based full-service brokerage but has been transformed under CEO Ronald Kruszewski through a slew of acquisitions into a globally competitive wealth manager, investment bank, and retail and institutional brokerage. The firm generated $5.5 billion in revenue in 2025, with roughly two-thirds derived from wealth management and one-third derived from trading and investment banking.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.